- Home
- AMIX vs VRAX Comparison
AMIX vs VRAX Comparison
Compare AMIX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- VRAX
- Stock Information
- Founded
- AMIX 2014
- VRAX 2013
- Country
- AMIX United States
- VRAX United Kingdom
- Employees
- AMIX N/A
- VRAX N/A
- Industry
- AMIX
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AMIX
- VRAX Health Care
- Exchange
- AMIX NYSE
- VRAX Nasdaq
- Market Cap
- AMIX 4.4M
- VRAX 5.9M
- IPO Year
- AMIX N/A
- VRAX 2022
- Fundamental
- Price
- AMIX $1.70
- VRAX $1.06
- Analyst Decision
- AMIX Strong Buy
- VRAX Strong Buy
- Analyst Count
- AMIX 1
- VRAX 1
- Target Price
- AMIX $5.00
- VRAX $3.00
- AVG Volume (30 Days)
- AMIX 152.4K
- VRAX 290.4K
- Earning Date
- AMIX 05-30-2025
- VRAX 02-05-2025
- Dividend Yield
- AMIX N/A
- VRAX N/A
- EPS Growth
- AMIX N/A
- VRAX N/A
- EPS
- AMIX N/A
- VRAX N/A
- Revenue
- AMIX N/A
- VRAX $84,872.00
- Revenue This Year
- AMIX N/A
- VRAX $5,169.18
- Revenue Next Year
- AMIX N/A
- VRAX $66.97
- P/E Ratio
- AMIX N/A
- VRAX N/A
- Revenue Growth
- AMIX N/A
- VRAX 7.03
- 52 Week Low
- AMIX $1.52
- VRAX $0.65
- 52 Week High
- AMIX $75.80
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- AMIX 39.78
- VRAX 49.23
- Support Level
- AMIX $2.10
- VRAX $0.91
- Resistance Level
- AMIX $2.82
- VRAX $1.07
- Average True Range (ATR)
- AMIX 0.21
- VRAX 0.07
- MACD
- AMIX -0.02
- VRAX 0.02
- Stochastic Oscillator
- AMIX 1.75
- VRAX 68.18
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.